scholarly journals Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study

2018 ◽  
Vol 182 (4) ◽  
pp. 495-503 ◽  
Author(s):  
Sundar Jagannath ◽  
Jacob Laubach ◽  
Ellice Wong ◽  
Keith Stockerl-Goldstein ◽  
Cara Rosenbaum ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Smouldering Multiple Myeloma

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

2020 ◽  
Vol 21 (2) ◽  
pp. 207-221 ◽  
Author(s):  
Sagar Lonial ◽  
Hans C Lee ◽  
Ashraf Badros ◽  
Suzanne Trudel ◽  
Ajay K Nooka ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study ◽  
Open Label Phase

Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma

2017 ◽  
Vol 59 (5) ◽  
pp. 1271-1273 ◽  
Author(s):  
Massimo Offidani ◽  
Laura Corvatta ◽  
Anna Marina Liberati ◽  
Stefano Pulini ◽  
Stelvio Ballanti ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Refractory Multiple Myeloma ◽  
Phase 2 Study

scholarly journals Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile

2008 ◽  
Vol 99 (6) ◽  
pp. 1243-1250 ◽  
Author(s):  
Yutaka Hattori ◽  
Shin-ichiro Okamoto ◽  
Naoki Shimada ◽  
Tsunayuki Kakimoto ◽  
Kunihiko Morita ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Prognostic Factors ◽  
Toxicity Profile ◽  
Phase 2 ◽  
Phase 2 Study ◽  
Thalidomide Treatment

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan

2019 ◽  
Vol 111 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Kohmei Kubo ◽  
Mitsuo Hori ◽  
Kensuke Ohta ◽  
Hiroshi Handa ◽  
Kiyohiko Hatake ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 2 Study ◽  
Open Label Phase

Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES)

2019 ◽  
Vol 19 (10) ◽  
pp. e16-e17 ◽  
Author(s):  
Ajai Chari ◽  
Hartmut Goldschmidt ◽  
Jesus San-Miguel ◽  
Helen McCarthy ◽  
Kenshi Suzuki ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Phase 2 ◽  
Open Label ◽  
Treatment Regimens ◽  
Multicenter Phase ◽  
Phase 2 Study
Sign in / Sign up

Export Citation Format

Share Document